Sanofi
SNY Healthcare Drug Manufacturers General
Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024. In the quarter to June 2026, revenue grew 17.4%, EPS fell 90.8%, free cash flow fell 45.1% and total debt rose 8.23%, each against the same quarter a year earlier. Dividend growth for three consecutive years.
Follow SNY
A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Operating Cash Flow |
5,398.42 | — | 12,162.55 | — |
+8 more quarters Free account |
Investing cash flow |
(3,073.02) | — | (2,768.54) | — | |
Financing cash flow |
(3,874.12) | — | (9,285.40) | — | |
Exchange Rate Adjustment |
22.09 | — | (53.18) | — | |
Discontinued Operations and Adjustments |
— | — | 188.94 | — | |
Change in Cash |
(1,526.62) | — | 244.38 | — | |
Beginning Cash |
8,909.77 | — | 8,418.75 | — | |
Ending Cash |
7,383.15 | — | 8,663.13 | — | |
Dividends Paid (Common) |
(5,753.04) | 0.00 | (5,442.03) | 5,447.83 | |
Net Cash/Marketcap |
0.00 | 0.00 | 0.00 | 0.00 |